Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your eyes may reveal your meds: new study investigates

NCT ID NCT07389473

Knowledge-focused Sponsor: Gaize Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special eye-tracking device (Gaize) can identify changes in eye movement patterns caused by long-term use of psychiatric medications. Researchers will observe 50 adults with conditions like ADHD, depression, or anxiety who have been on medication for over 3 months. The goal is to see if the device can accurately detect medication effects, which could help in future assessments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participant population is limited to the city of Philadelphia, PA

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged between 18 and 65, having given written informed consent to participate in the research trial. * Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months. * Normal or corrected to normal vision using either glasses or contact lenses, or surgery. Exclusion Criteria: * Enrolled in, or participated in another clinical trial within 30 days before the study * Having a prosthetic eye, missing eye, or wearer of an eye patch LASIK or other eye surgery within the prior 21 days. * Had your eyes dilated by a medical doctor in the previous 24 hours. * Photosensitive epilepsy * Diagnosed with clinical blindness * Medical Conditions: Participants with medical conditions or medications that could significantly affect cognitive and motor functions are excluded. Participants with conditions such as Glaucoma, macular degeneration, cataracts, lazy eye (amblyopia), or optic neuritis, or genetic anisocoria (unequal pupil size) will be excluded. * Current or past head inject/ traumatic brain injury (TBI) * Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with psychiatric medications. * History of Severe Motion Sickness: Participants with a history of severe motion sickness in VR environments may be excluded, as they may not tolerate the VR headset well. * Potential participants who are unable to provide consent for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder bipolar disorder depressive disorder generalized anxiety disorder mood disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD Anxiety disorder, generalized Bipolar disorder (BPD) Depression disorders Mood disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gaize

    RECRUITING

    Philadelphia, Pennsylvania, 19130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.